Cargando…
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
A severe acute respiratory syndrome coronavirus (SARS-CoV-2) vaccine is needed to control the global coronavirus infectious disease (COVID-19) public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of beta...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581537/ https://www.ncbi.nlm.nih.gov/pubmed/32756549 http://dx.doi.org/10.1038/s41586-020-2622-0 |
| _version_ | 1783598998482845696 |
|---|---|
| author | Corbett, Kizzmekia S. Edwards, Darin K. Leist, Sarah R. Abiona, Olubukola M. Boyoglu-Barnum, Seyhan Gillespie, Rebecca A. Himansu, Sunny Schäfer, Alexandra Ziwawo, Cynthia T. DiPiazza, Anthony T. Dinnon, Kenneth H. Elbashir, Sayda M. Shaw, Christine A. Woods, Angela Fritch, Ethan J. Martinez, David R. Bock, Kevin W. Minai, Mahnaz Nagata, Bianca M. Hutchinson, Geoffrey B. Wu, Kai Henry, Carole Bahi, Kapil Garcia-Dominguez, Dario Ma, LingZhi Renzi, Isabella Kong, Wing-Pui Schmidt, Stephen D. Wang, Lingshu Zhang, Yi Phung, Emily Chang, Lauren A. Loomis, Rebecca J. Altaras, Nedim Emil Narayanan, Elisabeth Metkar, Mihir Presnyak, Vlad Liu, Cuiping Louder, Mark K. Shi, Wei Leung, Kwanyee Yang, Eun Sung West, Ande Gully, Kendra L. Stevens, Laura J. Wang, Nianshuang Wrapp, Daniel Doria-Rose, Nicole A. Stewart-Jones, Guillaume Bennett, Hamilton Alvarado, Gabriela S. Nason, Martha C. Ruckwardt, Tracy J. McLellan, Jason S. Denison, Mark R. Chappell, James D. Moore, Ian N. Morabito, Kaitlyn M. Mascola, John R. Baric, Ralph S. Carfi, Andrea Graham, Barney S. |
| author_facet | Corbett, Kizzmekia S. Edwards, Darin K. Leist, Sarah R. Abiona, Olubukola M. Boyoglu-Barnum, Seyhan Gillespie, Rebecca A. Himansu, Sunny Schäfer, Alexandra Ziwawo, Cynthia T. DiPiazza, Anthony T. Dinnon, Kenneth H. Elbashir, Sayda M. Shaw, Christine A. Woods, Angela Fritch, Ethan J. Martinez, David R. Bock, Kevin W. Minai, Mahnaz Nagata, Bianca M. Hutchinson, Geoffrey B. Wu, Kai Henry, Carole Bahi, Kapil Garcia-Dominguez, Dario Ma, LingZhi Renzi, Isabella Kong, Wing-Pui Schmidt, Stephen D. Wang, Lingshu Zhang, Yi Phung, Emily Chang, Lauren A. Loomis, Rebecca J. Altaras, Nedim Emil Narayanan, Elisabeth Metkar, Mihir Presnyak, Vlad Liu, Cuiping Louder, Mark K. Shi, Wei Leung, Kwanyee Yang, Eun Sung West, Ande Gully, Kendra L. Stevens, Laura J. Wang, Nianshuang Wrapp, Daniel Doria-Rose, Nicole A. Stewart-Jones, Guillaume Bennett, Hamilton Alvarado, Gabriela S. Nason, Martha C. Ruckwardt, Tracy J. McLellan, Jason S. Denison, Mark R. Chappell, James D. Moore, Ian N. Morabito, Kaitlyn M. Mascola, John R. Baric, Ralph S. Carfi, Andrea Graham, Barney S. |
| author_sort | Corbett, Kizzmekia S. |
| collection | PubMed |
| description | A severe acute respiratory syndrome coronavirus (SARS-CoV-2) vaccine is needed to control the global coronavirus infectious disease (COVID-19) public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins(1). Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). Here, we show that mRNA-1273 induces both potent neutralizing antibody responses to wild-type (D614) and D614G mutant(2) SARS-CoV-2 and CD8 T cell responses and protects against SARS-CoV-2 infection in lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in Phase 3 efficacy evaluation. |
| format | Online Article Text |
| id | pubmed-7581537 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-75815372021-02-05 SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness Corbett, Kizzmekia S. Edwards, Darin K. Leist, Sarah R. Abiona, Olubukola M. Boyoglu-Barnum, Seyhan Gillespie, Rebecca A. Himansu, Sunny Schäfer, Alexandra Ziwawo, Cynthia T. DiPiazza, Anthony T. Dinnon, Kenneth H. Elbashir, Sayda M. Shaw, Christine A. Woods, Angela Fritch, Ethan J. Martinez, David R. Bock, Kevin W. Minai, Mahnaz Nagata, Bianca M. Hutchinson, Geoffrey B. Wu, Kai Henry, Carole Bahi, Kapil Garcia-Dominguez, Dario Ma, LingZhi Renzi, Isabella Kong, Wing-Pui Schmidt, Stephen D. Wang, Lingshu Zhang, Yi Phung, Emily Chang, Lauren A. Loomis, Rebecca J. Altaras, Nedim Emil Narayanan, Elisabeth Metkar, Mihir Presnyak, Vlad Liu, Cuiping Louder, Mark K. Shi, Wei Leung, Kwanyee Yang, Eun Sung West, Ande Gully, Kendra L. Stevens, Laura J. Wang, Nianshuang Wrapp, Daniel Doria-Rose, Nicole A. Stewart-Jones, Guillaume Bennett, Hamilton Alvarado, Gabriela S. Nason, Martha C. Ruckwardt, Tracy J. McLellan, Jason S. Denison, Mark R. Chappell, James D. Moore, Ian N. Morabito, Kaitlyn M. Mascola, John R. Baric, Ralph S. Carfi, Andrea Graham, Barney S. Nature Article A severe acute respiratory syndrome coronavirus (SARS-CoV-2) vaccine is needed to control the global coronavirus infectious disease (COVID-19) public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins(1). Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). Here, we show that mRNA-1273 induces both potent neutralizing antibody responses to wild-type (D614) and D614G mutant(2) SARS-CoV-2 and CD8 T cell responses and protects against SARS-CoV-2 infection in lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in Phase 3 efficacy evaluation. 2020-08-05 2020-10 /pmc/articles/PMC7581537/ /pubmed/32756549 http://dx.doi.org/10.1038/s41586-020-2622-0 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
| spellingShingle | Article Corbett, Kizzmekia S. Edwards, Darin K. Leist, Sarah R. Abiona, Olubukola M. Boyoglu-Barnum, Seyhan Gillespie, Rebecca A. Himansu, Sunny Schäfer, Alexandra Ziwawo, Cynthia T. DiPiazza, Anthony T. Dinnon, Kenneth H. Elbashir, Sayda M. Shaw, Christine A. Woods, Angela Fritch, Ethan J. Martinez, David R. Bock, Kevin W. Minai, Mahnaz Nagata, Bianca M. Hutchinson, Geoffrey B. Wu, Kai Henry, Carole Bahi, Kapil Garcia-Dominguez, Dario Ma, LingZhi Renzi, Isabella Kong, Wing-Pui Schmidt, Stephen D. Wang, Lingshu Zhang, Yi Phung, Emily Chang, Lauren A. Loomis, Rebecca J. Altaras, Nedim Emil Narayanan, Elisabeth Metkar, Mihir Presnyak, Vlad Liu, Cuiping Louder, Mark K. Shi, Wei Leung, Kwanyee Yang, Eun Sung West, Ande Gully, Kendra L. Stevens, Laura J. Wang, Nianshuang Wrapp, Daniel Doria-Rose, Nicole A. Stewart-Jones, Guillaume Bennett, Hamilton Alvarado, Gabriela S. Nason, Martha C. Ruckwardt, Tracy J. McLellan, Jason S. Denison, Mark R. Chappell, James D. Moore, Ian N. Morabito, Kaitlyn M. Mascola, John R. Baric, Ralph S. Carfi, Andrea Graham, Barney S. SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness |
| title | SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness |
| title_full | SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness |
| title_fullStr | SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness |
| title_full_unstemmed | SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness |
| title_short | SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness |
| title_sort | sars-cov-2 mrna vaccine design enabled by prototype pathogen preparedness |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581537/ https://www.ncbi.nlm.nih.gov/pubmed/32756549 http://dx.doi.org/10.1038/s41586-020-2622-0 |
| work_keys_str_mv | AT corbettkizzmekias sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT edwardsdarink sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT leistsarahr sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT abionaolubukolam sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT boyoglubarnumseyhan sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT gillespierebeccaa sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT himansusunny sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT schaferalexandra sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT ziwawocynthiat sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT dipiazzaanthonyt sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT dinnonkennethh sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT elbashirsaydam sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT shawchristinea sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT woodsangela sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT fritchethanj sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT martinezdavidr sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT bockkevinw sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT minaimahnaz sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT nagatabiancam sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT hutchinsongeoffreyb sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT wukai sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT henrycarole sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT bahikapil sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT garciadominguezdario sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT malingzhi sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT renziisabella sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT kongwingpui sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT schmidtstephend sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT wanglingshu sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT zhangyi sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT phungemily sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT changlaurena sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT loomisrebeccaj sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT altarasnedimemil sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT narayananelisabeth sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT metkarmihir sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT presnyakvlad sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT liucuiping sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT loudermarkk sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT shiwei sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT leungkwanyee sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT yangeunsung sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT westande sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT gullykendral sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT stevenslauraj sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT wangnianshuang sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT wrappdaniel sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT doriarosenicolea sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT stewartjonesguillaume sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT bennetthamilton sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT alvaradogabrielas sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT nasonmarthac sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT ruckwardttracyj sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT mclellanjasons sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT denisonmarkr sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT chappelljamesd sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT mooreiann sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT morabitokaitlynm sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT mascolajohnr sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT baricralphs sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT carfiandrea sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness AT grahambarneys sarscov2mrnavaccinedesignenabledbyprototypepathogenpreparedness |